Thromb Haemost 2006; 95(04): 600-605
DOI: 10.1160/TH05-07-0510
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors

A multi-centre, randomised, double-blind, cross-over trial
Khan Kavakli
1  University of Ege, Izmir, Turkey
,
Mike Makris
2  Royal Hallamshire Hospital, Sheffield, United Kingdom
,
Bulent Zulfikar
3  Istanbul University, Istanbul, Turkey
,
Elizabeth Erhardtsen
4  NovoNordisk A/S, Bagsvaerd, Denmark
,
Zvi S. Abrams
4  NovoNordisk A/S, Bagsvaerd, Denmark
,
Gili Kenet
5  Sheba Medical Centre, Tel-Hashomer, Israel
,
for the NovoSeven ® trial (F7HAEM-1510) investigators› Author Affiliations
Financial support: This study was sponsored by Novo Nordisk A/S, Bagsvaerd, Denmark.
Further Information

Publication History

Received 21 July 2005

Accepted after resubmission 13 February 2006

Publication Date:
30 November 2017 (online)

Summary

The aim was to evaluate the efficacy and safety of two recombinant factor VIIa (rFVIIa) dose regimens for treating haemarthroses in patients with congenital haemophilia A or B and inhibitors. This was a multi-centre, randomised, cross-over, double-blind trial. Patients were randomly allocated to treat a first joint bleeding episode with one 270 µg/kg rFVIIa dose followed by two doses of placebo at 3-hour intervals and a second joint bleed with three single doses of 90 µg/kg rFVIIa at 3-hour intervals, or vice versa. Efficacy was evaluated using a novel and robust treatment response-rating scale based on patient-assessment of pain and joint mobility. Outcome was rated at different timepoints, and an effective or ineffective treatment response was determined. Treatment “preference” was defined as effective treatment with one regimen and ineffective with the other. Patients with equally effective or ineffective treatments had no “preference”. Treatment was rated as effective for 65% of patients using the 270 µg/kg dose versus 70% for the 90 µg/kg ×3 regimen. An equal “preference” was noted for the two regimens (21% for each; p = 0.637); most patients (58%) had no “preference”. 37/42 bleeding episodes (88%) were successfully treated with rFVIIa; additional haemostatic medications were administered for five episodes. No safety issues were identified. Administration of rFVIIa as a single 270 µg/kg dose to treat haemarthroses in patients with haemophilia and inhibitors was at least as efficacious and safe as the 90 µg/kg ×3 regimen.